Table 2

Risk of septic arthritis in patients with rheumatoid arthritis

nbDMARDAll anti-TNFEtanerceptInfliximabAdalimumab
Exposure time (years)11 42642 67118 55410 82713 289
Events (n)20179864152
Incident rate/1000 pyrs (95% CI)1.8 (1.1 to 2.7)4.2 (3.6 to 4.8)4.6 (3.7 to 5.7)3.8 (2.7 to 5.1)3.9 (2.9 to 5.1)
Unadjusted HR (95% CI)Ref2.5 (1.6 to 4.0)3.0 (1.8 to 4.8)2.2 (1.3 to 3.8)2.3 (1.4 to 3.8)
Adjusted HR (95% CI)Ref2.3 (1.2 to 4.4)2.5 (1.3 to 4.9)2.4 (1.0 to 5.8)1.9 (0.9 to 4.0)
  • Anti-TNF, anti-tumour necrosis factor; nbDMARD, non-biological disease-modifying antirheumatic drug; pyrs, patient years.